Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK/PD in dose optimization by Lim, Sazlyna Mohd Sazlly et al.
 Accepted Manuscript
Multidrug-resistant Acinetobacter baumannii infections: current
evidence on treatment options and role of PK/PD in dose optimization
Sazlyna Mohd Sazlly Lim , Fekade Bruck Sime , Jason Roberts
PII: S0924-8579(19)30046-9
DOI: https://doi.org/10.1016/j.ijantimicag.2019.02.016
Reference: ANTAGE 5655
To appear in: International Journal of Antimicrobial Agents
Received date: 22 November 2018
Accepted date: 26 February 2019
Please cite this article as: Sazlyna Mohd Sazlly Lim , Fekade Bruck Sime , Jason Roberts ,
Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and
role of PK/PD in dose optimization, International Journal of Antimicrobial Agents (2019), doi:
https://doi.org/10.1016/j.ijantimicag.2019.02.016
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service
to our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and
all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Highlights 
 In vitro synergy was seen in only a portion of MDR A. baumannii strains tested.  
 Majority of observational studies did not show added benefits of combination 
therapy. 
 No strong RCT data to support combination therapy. 
 Some novel agents are promising options for the treatment of MDR A. baumannii. 
 PK/PD optimized therapy is likely required to ensure a successful treatment.  
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Abstract  
 
Acinetobacter baumannii remains a difficult-to-treat pathogen that poses a significant 
challenge to clinicians and cost to the healthcare system. There is a lack of clinical efficacy 
data to aid in the selection of optimal treatment for multi-drug resistant (MDR) A. baumannii 
infections. This paper aims to review recent literature on the treatment of MDR A. baumannii 
and novel agents in the pipeline and discuss the clinical data supporting their use.  
Colistin has been widely studied as monotherapy or as part of combination therapy, but its 
use is limited due to nephrotoxicity. The clinical benefit of combination therapy, whether 
empirical or targeted, has yet to be demonstrated, due to a lack of definitive evidence from 
randomized controlled trials. Most available clinical studies are retrospective and lack control 
groups, which offers low-grade evidence. Novel agents such as cefiderocol, plazomicin, 
eravacycline, and sulbactam/ETX2514 combination are promising options for the treatment 
of different infection pathologies caused by MDR A. baumannii, but these have yet to be 
evaluated in randomized controlled trials. A better understanding of the pharmacokinetics 
(PK)/pharmacodynamics (PD) of the "old" antibiotics is required to optimize their dosing 
regimens to maximize bacterial killing, minimize toxicities and improve clinical outcomes. 
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1 Introduction 
There are increasing reports of nosocomial infections caused by Acinetobacter 
baumannii, a pathogen frequently identified as an etiologic agent in catheter-related 
bacteraemia, hospital-acquired or ventilator-associated pneumonia (VAP), urinary tract 
infections, surgical site and other types of wound infections [1].  A. baumannii is intrinsically 
resistant to many antibiotics and readily acquires resistance to others. It can survive on dry 
surfaces and inanimate objects for months. These characteristics have contributed to the 
spread of multidrug-resistant (MDR) A. baumannii strains [2, 3]. The risk factors for acquiring 
MDR A. baumannii include recent exposure to antibiotics, especially third-generation 
cephalosporins,  carbapenems and fluoroquinolones,  presence of central lines  or urinary 
catheters, severe disease, recent surgery, larger hospital size, prolonged ventilation, long  
intensive care unit (ICU) or hospital stay, exposure to infected or colonized patients and 
multiple medical procedures [4-6].  
MDR A. baumannii frequently harbour multiple resistance mechanisms, [7] which 
leaves us with few available treatment options. A. baumannii used to be susceptible to 
antibiotics such as ampicillin and nalidixic acid [8]. However, the number of treatment 
options has reduced drastically with increasing resistance. For example, epidemiological 
studies from various parts of the world reported that 70-90% of A. baumannii isolates were 
resistant to three or more antibiotics of different classes including carbapenems, penicillins, 
cephalosporins, aminoglycosides, polymyxins and fluoroquinolones (i.e., MDR) [9, 10].. There 
has also been an increase in reports of MDR A. baumannii isolates that are resistant to 
colistin, which is mostly considered like our last line of defence against these organisms [11, 
12]. 
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This review examines existing treatment options and new antibiotics, with promising 
activity against MDR A. baumannii, that have been recently approved or are in clinical 
development. 
 
2. Methods  
The PubMed, Embase and Cochrane Library databases were searched for articles 
published in the last ten years up to 1 August 2018. The main search terms were ‘multidrug-
resistant’, ‘Acinetobacter’, ‘treatment’ AND ‘combination’. Also, the reference lists of reports 
identified by this search strategy were searched to select relevant articles. Only articles 
published in English were included. We Included (1) in vitro and in vivo studies on antibiotic 
synergy against MDR A. baumannii, (2) clinical studies, both retrospective and prospective, 
describing the treatment of A. baumannii infections,  and (3) studies on novel antibiotics for 
A. baumannii infections.  One hundred sixty-one relevant articles were identified from our 
literature search and included in this review. 
 
3. Monotherapy vs. combination therapy – the current evidence 
3.1 In vitro and pre-clinical animal studies 
There are limited therapeutic options that exist for treating MDR A. baumannii. 
Combination therapy may be used by some clinicians to manage these infections despite 
little laboratory guidance as to the microbiological effectiveness of this approach. Synergy 
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testing methods have been used to assess the interaction of antibiotic combinations in vitro. 
These may provide predictive information regarding the use of antimicrobials in 
combinations. Many in vitro and in vivo animal studies have explored the possible synergy of 
antibiotics to overcome Acinetobacter spp. resistance. During this review, we found 50 in 
vitro and 15 in vivo animal studies, describing the effects of various antibiotic combinations 
against MDR A. baumannii. Their characteristics are presented in Supplementary Table 1[13-
62]  and Supplementary Table 2  [15, 35, 45, 55, 64-74].  
Most of these studies showed potential antibiotic combinations that could improve 
the treatment outcomes of MDR A. baumannii infections. However, the studies also show 
that in vitro synergy is observed only for a portion of strains tested. Antagonism was 
observed in about 20% of the in vitro studies, and combinations that displayed antagonistic 
effect include various tigecycline-based combinations, [24, 33, 39, 59] imipenem-based 
combinations, [28] tobramycin-based combinations, [30] and certain sulbactam-based 
combinations [53, 56, 59]. Unfortunately, there is limited understanding to date as to what 
type of strains are more susceptible to combination therapy.  Indeed this may be an 
important factor contributing to the lack of reproducibility of results from in vitro and animal 
model studies. It is also worth noting that broth microdilution is the recommended method 
of testing the minimum inhibitory concentration (MIC) of colistin [75]. This has obvious 
implications when interpreting the results of any in vitro or in vivo studies involving colistin, 
which employs MIC testing methods other than broth microdilution. 
3.2 Observational clinical studies 
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Our search identified 25 observational studies (23 retrospective and two prospective 
studies) that described treatment outcome for MDR Acinetobacter spp. infections. The 
characteristics of these studies are presented in Table 1.  
Of the observational studies (Table 1), 12 studies compared monotherapy to 
combination therapy, [76-87] nine studies compared different combination treatment 
regimens [83, 87-94] and six studies looked at different routes of administration of colistin, 
either inhaled or intrathecal/intraventricular [95-100]. More than 90% of these observational 
studies looked at patients with pneumonia, either as the sole site of infection or as a large 
majority from various sites of infection. Sample sizes range from 27 to 386. More than 50% of 
these studies explored the efficacy of polymyxin-based therapy, and 25% looked at the 
efficacy of tigecycline-based therapy. There are differences in the study design such as case 
definitions and inclusion/exclusion criteria. There were also differences in the dose of 
antibiotics prescribed, and most of these studies were carried out before 2012, which was 
when the recommendation for colistin loading dose first came.  
Of the 12 studies that compared the efficacy of combination versus monotherapy, 
only one study showed a significant difference in 30-day mortality [82]. This retrospective 
study included 101 patients with various sites of infection, mainly pneumonia. Patients were 
either given IV polymyxin B alone, at a dose of 1.5 to 3.0 mg/kg/day in two divided doses,  or 
in combination with other antibiotics (mainly meropenem, 69.7%). The mortality rate was 
42.4% in the combination therapy group and 67.7% in the monotherapy group (p = 0.030). 
The rate of microbiological eradication was not mentioned in the study.  
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Another study showed a significant difference in the rate of microbiological 
eradication in the combination therapy group when compared to monotherapy (79.9% vs. 
55.6%, p =  0.001) [83]. In this study, the authors compared colistin combination therapy with 
either carbapenem, sulbactam or other antibiotics, and colistin monotherapy. Colistin was 
given at a dose of 5mg/kg/day colistin base activity (CBA) in 2-3 divided doses, with renal 
adjustment. No loading dose was given to the patients. However, no difference was seen in 
the clinical response and 14-day mortality between the two groups. Other studies, however, 
did not demonstrate improved clinical or microbiological outcomes [77-81, 84-87].  
Two studies explored the clinical efficacy of colistin-glycopeptide combination 
compared to colistin monotherapy [76, 81]. One study did not observe a statistically 
significant difference in the mortality rate when comparing the two treatment arms [81], but 
the other showed that giving colistin with a glycopeptide for at least five days was protective 
against 30-day mortality [76]. 
Of the nine studies which compared different antibiotic combinations, three studies 
found a significant difference in their clinical outcome [88, 91, 93]. The first study compared 
tigecycline-based therapy (IV tigecycline 50 mg 12 hourly, after a loading dose of 100 mg ± 
other antibiotics), with non-tigecycline based combination therapy (IV imipenem/cilastatin 
500 mg and sulbactam 1 g 6 hourly) in 386 patients with hospital-acquired infections Lee, 
2013 #342}. Favourable clinical outcome was considerably higher in the tigecycline-based 
therapy group (69.1% vs. 50%, p = <0.001). However, microbiological eradication rate was 
better in the non-tigecycline based combination therapy group (11.7% vs. 1.1%, p = <0.001). 
The second study compared tigecycline-based therapy (IV tigecycline 50 mg 12 hourly, after a 
loading dose of 100 mg ± other antibiotics) with colistin-based therapy (IV colistin 2.5–5 
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mg/kg/day CBA in 2–3 divided doses ± other antibiotics), in 168 patients with MDR A. 
baumannii pneumonia [91]. Mortality was significantly lower in the colistin-based therapy 
(44% vs. 60.7%, p = 0.040). The third study compared tigecycline/imipenem combination 
therapy with sulbactam/imipenem combination therapy, in 84 patients with MDR A. 
baumannii VAP [93]. The standard dose of the antibiotics was used, but the exact dosing was 
not specified. This study found that the 30-day survival rate was significantly better in the 
tigecycline/imipenem combination therapy group compared to the sulbactam/imipenem 
combination therapy group (85.7% vs. 35.7%, p = 0.007). However, it is important to note 
that in the tigecycline group, patients were switched from sulbactam-based therapy to 
tigecycline-based therapy after failure to respond to 3-day sulbactam–imipenem/cilastatin 
therapy. Another study [90] comparing tigecycline-based therapy (IV tigecycline 50 mg 12 
hourly, after a loading dose of 100 mg ± other antibiotics) with sulbactam-based therapy (IV 
sulbactam 1 g or ampicillin/sulbactam 3 g (at a rate of 2:1) 6-8 hourly ± other antibiotics) 
found  that microbiological eradication was much higher in the sulbactam-based therapy 
group (63.5% vs. 33.3%, p = <0.001). Other studies, however, did not find a significant 
difference in clinical or microbiological outcomes for the various combination regimens 
investigated [83, 87, 89, 92, 94]. 
Of the six studies that explored different routes of polymyxin administration, five 
studies looked at the efficacy of inhaled colistin [95-99] and one looked at the efficacy of 
intrathecal/intraventricular (IT/IVT) polymyxin B [100]. Two studies observed superior 
microbiological eradication with inhaled colistin (nebulised colistin 2 MU 12 hourly) 
compared to systemic antibiotic therapies (61.1-84.6% vs. 10.3-29.6%, p = 0.001) [95, 96]. 
Neither study found a significant difference in 28-day mortality rate. Other studies found no 
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significant differences in clinical or microbiological outcomes, when comparing inhaled 
colistin with IV colistin for the treatment of MDR A. baumannii pneumonia [97-99].  
With regards to IT/IVT polymyxin B for the treatment of MDR A. baumannii 
meningitis/ventriculitis, one study reported significant differences in clinical and 
microbiological outcomes [100]. This study compared IT/IVT polymyxin B-based therapy 
(IT/IVT polymyxin B 50,000 units/day 12 hourly + IV polymyxin B 450,000 units 12 hourly ± 
other IV antibiotics) with other IV antibiotic therapies in 61 patients. Clinical efficacy was 
much higher in the IT/IVT group (95.6% vs. 23.7%, p = <0.001) and 28-day mortality was 
much lower (8.7% vs. 55.2%, p = 0.01). Microbiological clearance was also significantly higher 
in the IT/IVT group (91.3% vs. 18.4%, p = <0.001).  
A majority of these observational studies (Table 1) did not show any added benefits of 
combination vs. monotherapy or between different treatment regimens. However, there are 
several limitations observed with many studies listed in Table 1, which may affect the validity 
of the results obtained. In general, most of the observational studies are retrospective in 
nature, and as such may be limited by various factors such as poor quality or missing data, or 
absence of data on potential confounding factors. There are also limitations in the dosing 
regimens of antimicrobials used, such as a lack of loading dose for colistin or suboptimal 
dosing of other antimicrobials, such as sulbactam and tigecycline. As highlighted previously 
concerning the issue with colistin MIC testing, we note that most studies involving colistin did 
not use broth microdilution for testing of colistin MIC. Another point of relevance is that 
polymyxins have limited drug exposure in the lungs following parenteral administration, 
resulting in lower antibacterial activity and limited efficacy in the lungs, relative to other sites, 
as shown in several studies [101, 102]. 
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3.3 Randomized controlled trial data 
We found eight RCTs that compared different treatment regimens for MDR A. 
baumannii infections. The characteristics of these studies are presented in Table 2.  
All eight studies focused on the treatment of MDR A. baumannii pneumonia, mainly 
VAP. Seven out eight were open-labelled trials. Majority of the studies involving colistin did 
not mention the method of MIC testing used. Six out eight compared colistin monotherapy 
with colistin-based combination therapy [104-108, 110] and the remaining two measured the 
efficacy of inhaled colistin [103, 109]. Of the six studies which compared combination and 
monotherapy, only one study demonstrated improved clinical response with colistin-based 
combination therapy [108]. This recently published study compared colistin monotherapy (IV 
colistin 3 MU 8 hourly, with renal adjustment, without loading dose) with colistin/ampicillin- 
sulbactam combination therapy (IV colistin + IV ampicillin-sulbactam 6 g 6 hourly, both with 
renal adjustment), in 39 patients with VAP. The authors observed better clinical response in 
the combination group (70% vs. 15.8%, p = 0.001) but failed to demonstrate a difference in 
the microbiological outcome.  
Two other studies, however, found a better microbiological response in the 
combination group but failed to see any difference in their clinical outcome [105, 107 
153].The first study compared colistin monotherapy (IV colistin 2 MU 8 hourly, with renal 
adjustment, without loading dose) with colistin/rifampin combination therapy (IV colistin + IV 
rifampin 600 mg 12 hourly), in 210 patients with MDR A. baumannii infection, mainly VAP 
[105]. The authors found better microbiological eradication in the combination group, 
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compared to the monotherapy group (60.6% vs. 44.8%, p = 0.034), but did not see any 
difference in 30-day mortality rate in the two groups (43.3% vs. 42.9%, p = 0.950).  
The second study compared colistin monotherapy (IV colistin 5 mg/kg/day CBA, 
without loading dose) with colistin/fosfomycin combination therapy (IV colistin + IV 
fosfomycin 4 g 12 hourly) in 94 patients with MDR A. baumannii infections, mainly VAP [107]. 
The study showed a better microbiological response in the combination group, compared to 
the monotherapy group (100% vs. 81.2%, p = 0.010), but did not see any difference in clinical 
response in the two groups (59.6% vs. 55.3%, p = 0.835).  
Another recently published study, the AIDA trial, tested the hypothesis that 
combination therapy would reduce clinical failure from 45% with colistin monotherapy to 
30% with combination therapy. This study compared colistin monotherapy (IV colistin 4.5 MU 
12 hourly after a loading dose of 9 MU, with renal adjustment) with colistin/meropenem 
combination therapy (IV colistin + IV meropenem 2 g 8 hourly with 3-h infusion, both with 
renally adjusted doses) in 406 patients with carbapenem-resistant Gram-negative infections 
(mainly pneumonia and bacteraemia), mostly due to MDR A. baumannii (312/406, 77%)  
[104]. One hundred ninety-eight patients were randomized into the colistin monotherapy 
group, and 208 patients were into the combination therapy group. The baseline patient 
clinical characteristics and demographics were comparable between the two groups. This 
study, however, failed to observe any superiority of combination therapy. There was no 
statistically significant difference in the primary outcome between the monotherapy vs. 
combination therapy (clinical failure at day 14, 73% vs. 79%, p = 0.172), or the secondary 
outcomes, which included microbiological failure (35% vs. 31%, p = 0.489), in the treatment 
of MDR A. baumannii pneumonia or bacteraemia. By day 14, 32% of patients in the 
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monotherapy arm and 34% of patients in the combination therapy arm had died (p = 0.786), 
and of the surviving patients, no improvement or deterioration in SOFA occurred.  
Furthermore, a subgroup analysis of the AIDA trial also noticed a similar finding when 
comparing colistin monotherapy to colistin/meropenem combination therapy in patients 
with carbapenem-resistant, colistin-resistant A. baumannii [111]. The authors found that 
colistin/meropenem combination therapy was significantly associated with higher mortality 
among those with colistin-resistant isolates (OR 2.956, 95%CI 1.180-7.408) when compared 
to the monotherapy arm. However, this association was not seen in colistin-susceptible 
strains (OR 0.943, 95%CI 0.640-1.389).  
Overall, similar limitations observed in the observational studies, were found in these 
RCTs as well. Factors such as the lack of loading dose or suboptimal dosing for colistin, or 
suboptimal dosing of other antimicrobials, such as sulbactam, rifampin, and fosfomycin, lack 
of information regarding the method used for colistin MIC testing, and limited penetration of 
polymyxins into the lungs need to be considered when evaluating these RCTs. There appears 
to be no strong RCT data to support combination therapy, although some findings suggest 
that there might be a benefit of treating MDR A. baumannii pneumonia with colistin in 
combination with high-dose ampicillin-sulbactam, rifampin [105] or Fosfomycin [107]. In view 
that these RCTs mainly included patients with pneumonia, it is unclear whether these 
regimens would have similar outcomes for other sites of infection.  
 
4. Optimised dosing of antibiotics to treat MDR A. baumannii 
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Given the challenges of providing effective treatment of infections caused by MDR A. 
baumannii, applying pharmacokinetic/pharmacodynamics (PK/PD) concepts to optimise 
dosing for individual patients should be considered an essential component of care. PK/PD 
optimized antibiotic doses or altered routes of administration are likely required to ensure a 
successful treatment outcome while minimizing side effects and emergence of resistance. 
PK/PD analyses describe the antibiotic exposure associated with maximal effect for an 
antibiotic and are critical determinants in establishing the dosing regimens [112]. Three 
patterns of antimicrobial activity [113, 114] and three PK/PD indices have been described, % 
fT>MIC (percentage of a 24-h time period that the unbound drug concentration exceeds the 
MIC), fCmax/MIC (maximal unbound drug concentration) and fAUC/MIC (area under the 
unbound drug concentration-time curve). Several studies have looked at dose optimization of 
currently available antibiotics for the treatment of MDR A. baumannii infections. The 
characteristics of these studies are presented in Table 3.  
As an example, based on murine thigh and lung infection models of A. baumannii, 
PK/PD analysis of sulbactam demonstrated that the %fT>MIC is most predictive of bacterial 
killing [129]. The authors concluded that sulbactam was sufficiently bactericidal when a 
%fT>MIC  of >60% against A. baumannii thigh infection and >40% against A. baumannii lung 
infection was achieved. This suggests that to maximize the bactericidal activity of sulbactam, 
blood sulbactam concentrations should be maintained above MIC for prolonged periods. In 
patients with severe sepsis, a target attainment of 60% fT>MIC for A. baumannii strains with a 
MIC of sulbactam of 4 mg/L, is more likely to be achieved when sulbactam is administered by 
a 4-h infusion of 1 g every 8 h, as demonstrated by a PK/PD study [126]. The authors of this 
study concluded that for pathogens with MICs of >4 mg/L, sulbactam should be given at a 
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higher dosage regimen of at least 1 g every 6 h by a 4-h infusion. PK/PD analysis has also 
helped to optimize dosing of sulbactam in patients with different renal functions, as shown 
by Yokoyama et al. [130]. The study demonstrated that in a patient with a creatinine 
clearance of 15 ml/min, a sulbactam dose of 1 g twice daily achieves a 60% fT>MIC  when the 
MIC of sulbactam against A. baumannii is 4 mg/L. A higher dose of 2 g four times daily is 
needed to achieve the same PK/PD target in a patient with a creatinine clearance of 90 
ml/min.  
The recent revitalisation of the long-neglected antibiotic, colistin, is another best 
examples showcasing the significant role of PK/PD in optimising existing and old antibiotics 
against MDR infections. Animal PK/PD models were used to identify fAUC/MIC as the best 
measure of colistin exposure that correlates well with bacterial killing [131]. Against A. 
baumannii, the fAUC/MIC values required to achieve stasis and 1-log kill were 1.57–6.52 and 
8.18–42.1 respectively in a lung infection model; and 1.89 – 7.41 and 6.98 – 13.6 respectively 
in a thigh infection model [131]. For a 2-log kill, the fAUC/MIC values raged 7.4 to 17.6 [101]. 
These PK/PD data, in combination with those from clinical pharmacokinetic and 
toxicodynamic studies were used for the development of dosing guidelines (Table 3) [132, 
133].  
For carbapenems, the PK/PD index that correlates with bacterial killing is %fT>MIC. One 
study suggested that the PK/PD targets for bacteriostatic and maximal bactericidal activity of 
carbapenems occur with a %fT>MIC of ∼20 and ∼40%, respectively [134]. An A. baumannii 
murine thigh infection model then demonstrated that the fT>MIC values of 23.7%, 32.8%, and 
47.5% resulted in stasis, 1-log reductions, and 2-log reductions in bacterial density after 24 h, 
respectively [135]. A subsequent PK/PD analysis on meropenem then revealed that the 
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probability of achieving 40% fT>MIC following a bolus injection of 1 g every 8h, a 3-hour 
infusion of 1 g every 8h, and a 3-hour infusion of 2 g every 8h were 87.7%, 98.8%, and 99.9%. 
This finding suggests that prolonged infusion maximizes the bactericidal activity of 
meropenem against A. baumannii with MIC of 4 mg/L [125]. 
The PK/PD index associated with bacterial killing by fosfomycin has been reported to 
be the % fT>MIC  with a target of 60-70 [136]. Based on a Monte Carlo simulation, Menegucci 
et al. found that target attainment of 70% fT>MIC  for pathogens with MIC of 32 mg/L is only 
achievable when fosfomycin is administered as a 3-hour infusion at a minimum dose of 4 g 
every 8h [31]. 
For tigecycline, the PK/PD index associated with therapeutic efficacy is fAUC/MIC 
[137]. Based on exposure-response analyses of tigecycline, the fAUC/MIC target associated 
with microbiological eradication ranged from 6-18, depending on the site of infection [137-
139]. The target ratios for skin or skin structure infections and intraabdominal infections are 
>17.9 and >6.9 respectively. These target values in combination with clinical PK data can be 
used for appraisal of existing dosing regimens. For example, an in silico analysis evaluation of 
the current recommended dose of 50 mg and 100 mg twice daily in skin and skin structure 
infections, demonstrated that the cumulative fraction response in the Gram-negative 
bacteria isolates, was only 54.67%, even when given at the highest recommended dose [127]. 
Whereas, in intra-abdominal infections, the cumulative fraction response against Gram-
negative bacteria isolates, ranges from 48% to 88%. These results suggest that current dosing 
recommendation of tigecycline should be adjusted to ensure optimal exposure.  
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Table 4 summarizes the PK/PD index and the optimal magnitude of the antibiotics 
discussed in this chapter. Table 5 summarizes the recommended dosing regimens of 
currently available antibiotics for the treatment of MDR A. baumannii. 
 
5. New antibiotics for treating MDR infections 
With limited antibiotics that are active against MDR A. baumannii, clinicians and 
researchers look to a new and novel agent that could hold this promise. There are several 
antibiotics, either in the pipeline or already approved, for the treatment of MDR Gram-
negative organisms. Examples of which include, ceftazidime/avibactam, 
aztreonam/avibactam, cefepime/zidebactam, imipenem/relebactam, 
meropenem/vaborbactam, ceftolozane/tazobactam, cefiderocol, plazomicin and 
eravacycline. However, the efficacy of these new agents against MDR Acinetobacter spp. 
remains a question and requires further exploration. Table 6 summarizes the new agents and 
their activity against MDR Acinetobacter spp. Table 7 summarizes the optimal PK/PD index for 
novel agents with in vitro activity against MDR A. baumannii. Of note, there is a lack of PK/PD 
target assessment studies against MDR A. baumannii. Most studies were done on Klebsiella 
pneumoniae and Pseudomonas aeruginosa [144-149]. 
5.1 Cefiderocol 
Cefiderocol (S-649266) is a new siderophore cephalosporin antibiotic with an iron 
chelating siderophore moiety, which contributes to its potency against Gram-negative 
bacteria [163, 183]. It is actively transported into the periplasmic space through the outer 
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membrane where it inhibits cell wall synthesis [184]. Cefiderocol is more stable against 
various beta-lactamases, including class A, B, C and D carbapenemases [185, 186]. Ito-
Horiyama et al. demonstrated that catalysis by various carbapenemases, including OXA-23, 
for S-649266 was 260-fold lower than that of meropenem [186]. 
Pharmacodynamic assessments of cefiderocol demonstrated that %fT>MIC was the 
PK/PD index that best predicted the bacteriostatic or bactericidal activity of this agent [187, 
188]. Subsequently, based on a P. aeruginosa neutropenic murine thigh model, the PK/PD 
targets for stasis and 1-log10 and 2-log10 reductions were found to be 44.4-94.7, 50.2-97.5 
and 62.1-100 %, respectively [148]. In this PD study, the MIC of P. aeruginosa ranges from 
0.063-0.5 µg/mL. Katsube et al. then looked at target attainment in patients with varying 
renal functions using Monte Carlo simulation [143]. The simulation demonstrated that 2 g 
every 8h with either 1- and 3-hr infusion is likely to achieve 75% fT>MIC against susceptible 
Gram-negative bacteria including A. baumannii. For patients with augmented renal function 
(creatinine clearance ≥ 120 mL/min), 2 g every 6h with 3-hr infusion is likely to achieve 75% 
fT>MIC against susceptible organisms. The study also suggested the need of supplemental 
dose immediately after intermittent haemodialysis to achieve similar PK/PD target.  
5.2 Plazomicin 
Plazomicin (ACHN-490) is a semisynthetic aminoglycoside derived from sisomicin 
[189]. Its structural modifications made this molecule stable in the presence of most 
aminoglycoside-modifying enzymes (AMEs). Plazomicin was shown to be more potent than 
sisomicin, amikacin, and gentamicin, against various Gram-negative bacilli, carrying one or 
more AMEs, including A. baumannii and other Acinetobacter spp. (MIC90 32 mg/L)  [189].  
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fAUC/MIC ratio was identified as the PK/PD index associated with 1- to 2-log10 colony 
forming unit (CFU) reduction for plazomicin, based on a carbapenem-resistant K. pneumoniae 
neutropenic murine lung and thigh infection model [144, 181]. The fAUC/MIC ratio target 
values associated with a 2-log10 reduction are 32-39 for lung infection 
 [181]. For thigh 
infection, the fAUC/MIC ratio target value associated with a 1-log10 reduction is 95 [144].  
5.3 Other novel agents 
Eravacycline is a novel fluorocycline antibiotic which can overcome resistance to 
tetracycline-specific efflux and ribosomal protection mechanisms [190]. Its bacteriostatic or 
bactericidal activity was found to best correlate with fAUC/MIC [149, 191]. The target ratios 
associated with net stasis and the 1-log10 reduction were 27.97 ± 8.29 and 32.60 ± 10.85, 
respectively, based on an Escherichia coli neutropenic murine thigh infection model [149]. 
However, Thabit et al. found that the fAUC/MIC magnitude associated with 1-log reduction is 
5.6 ± 5, when tested against MDR Enterobacteriaceae, in an immunocompetent murine thigh 
infection model [182]. 
Delafloxacin is a novel fluoroquinolone with chemical properties that allow it to exist 
largely deprotonated at acidic pHs which improved its potency in the lower pH infective 
environments. As with other fluoroquinolones, the PK/PD index associated with bacterial 
killing of delafloxacin is the fAUC/MIC [146, 147]. Based on a K. pneumoniae neutropenic 
murine lung infection model by Thabit et. al., [147] the PK/PD ratio magnitude required to 
achieve 1-log reduction is 9.6, which is significantly lower than the value observed by Lepak 
et. al., which was 80-200 [146]. However, there was a difference in the susceptibility of the K. 
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pneumoniae isolates used in both studies, whereby the infection model by Lepak et al. was 
tested against extended-spectrum beta-lactamase-producing K. pneumoniae isolates.  
ETX2514 is a diazabicyclooctanone beta-lactamase inhibitor, which has an extended 
spectrum of activity that covers of a wide array of class D enzymes, and improved potency 
against class A and C beta-lactamases [174]. It works by binding to the penicillin-binding 
proteins, which are the same targets as for beta-lactams. Durand-Réville et al. demonstrated 
that ETX2514 could fully restore beta-lactam activity against class A, C and D-expressing 
strains of A. baumannii, when combined with piperacillin, meropenem or sulbactam [174]. 
The study showed that the most potent combination against A. baumannii was sulbactam–
ETX2514, whereby ETX2514 can reduce the MIC of sulbactam by up to 6-fold. For 
sulbactam/ETX2514, the PK/PD index associated with bacterial killing is the % fT>MIC  
(sulbactam) and %T>CT  (time above the critical threshold) (ETX2514), with a target value of 
50 for both sulbactam and ETX2514 [145]. Subsequent PK/PD analysis then revealed that 1 
gm of sulbactam: 0.5 gm of ETX2514 via a 3 hr infusion every 6h  is likely to achieve the 
PK/PD target when tested against A. baumannii with MICs of ≤4 mg/L [145]. 
 
6. Conclusion  
A. baumannii infections are exceedingly difficult to treat. The prevalence of MDR 
strains is increasing, and knowledge of optimal treatment is limited. Colistin has been widely 
studied as monotherapy, or as part of combination therapy, but its use is limited due to 
nephrotoxicity. The clinical benefit of combination therapy, whether empirical or targeted, 
has yet to be demonstrated although in vitro studies have reported synergistic effects 
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between various antibiotics against MDR A. baumannii. Available clinical studies are 
unfortunately retrospective and lack control groups, which offers low-grade evidence. A 
better understanding of the PK/PD of the "old" antibiotics is required to optimize their dosing 
regimens for maximal bacterial killing. Novel agents such as cefiderocol, plazomicin, 
eravacycline, and sulbactam/ ETX2514 combination are promising options for the treatment 
of MDR A. baumannii, but these have yet to be evaluated in randomized controlled trials.  
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Table 1: Characteristics and outcomes of the studies reporting on the treatment of MDR Acinetobacter spp. infections 
Reference 
Study 
period 
Study design 
Number 
of 
patients 
Study objective 
Site of 
infection 
Treatment given Dose of antimicrobials Clinical outcome p-value  
Microbiological 
outcome  
p-value 
Petrosillo 
(2014) 
[76] 
2010-
2011 
Retrospective, 
cohort 
103 
Compare 
monotherapy and 
combination 
therapy 
Mainly VAP 
Colistin alone** 
IV colistimethate sodium 4-8 
MU/day, with or without 
loading dose of 4.5-9 MU 
30-day mortality 
27.9% 
0.900 - - 
Colistin + 
vancomycin/teicoplanin
** 
IV colistin + IV vancomycin 2 
g/day, with or without loading 
dose of 15 mg/kg OR IV 
teicoplanin 400 mg/day 
30-day mortality 
33.3% 
However, Cox regression analysis of risk factors for 30-day mortality showed that a colistin-glycopeptide combination was protective of 30-day mortality if administered for ≥ 5 days (HR, 0.42; 95% CI, 
0.19 to 0.93; p  0.03). 
 
Kalin 
(2014) 
[77]  
2011 
Retrospective, 
cohort 
89 
Compare 
monotherapy and 
combination 
therapy 
VAP 
Colistin alone** 
IV colistimethate sodium 2.5 
mg/kg q12h, with renal 
adjustment 
Clinical cure 29.8%, 
mortality 51.9% 
0.500, 
0.530 
Bacteriological 
clearance 72.3% 
0.28 
Colistin + sulbactam** IV sulbactam 3 g q8h 
Clinical cure 40%, 
mortality 73% 
Bacteriological 
clearance 85.7% 
Lopez-
Cortez 
(2014)[78] 
2010 
Prospective, 
observational 
cohort 
101 
Compare 
monotherapy and 
combination therapy 
Mainly 
pneumonia 
Combination therapy 
Colistin + tigecycline (27.3%) and 
carbapenem + tigecycline 
(12.1%) 
30-day mortality 
24.2% 
0.940 - - 
Monotherapy 
Colistin (67.6%) and 
carbapenems (14.7%) 
30-day mortality 
23.5% 
Balkan 
(2015)[79]  
2009-
2012 
Retrospective, 
cohort 
107 
Compare 
monotherapy and 
combination therapy 
Bacteraemia 
Colistin monotherapy 
IV colistin 2.5–5.0 mg/kg/day, no 
loading dose 
Clinical cure 31.4%, 
14-day mortality 
52.8% 
0.450, 
0.360 
Microbiological 
eradication 69% 
0.13 
Non-colistin based 
combination therapy 
Most common combination: 
cefoperazone/sulbactam + 
aminoglycoside, carbapenem + 
aminoglycoside, carbapenem + 
Clinical cure 42.9%, 
14-day mortality 
47.2% 
Microbiological 
eradication 83% 
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tigecycline and tigecycline + 
aminoglycoside, dose not 
specified 
Yilmaz 
(2015)[80]  
2011-
2013 
Retrospective, 
cohort 
70 
Compare 
monotherapy and 
combination therapy 
VAP 
Colistin monotherapy** 
IV colistin 2.25 MU q8h or 4.5 
MU q12h, with renal adjustment 
Clinical response 
76.5%, 28-day 
mortality 41.2% 
0.350, 
0.530 
Microbiological 
response 52.9% 
0.23 
Colistin/carbapenem 
combination therapy** 
IV imipenem 500 mg IV q6h or IV 
meropenem 1 g q8h (prolonged 
infusion), with renal adjustment 
Clinical response 
63.6%, 28-day 
mortality 48.5% 0.530, 
0.210 
Microbiological 
response 63.6% 
0.16 
Colistin/sulbactam 
combination therapy** 
IV sulbactam 1 g q8h, with renal 
adjustment 
Clinical response 
55.0%, 28-day 
mortality 70% 
Microbiological 
response 60.0% 
Garnacho-
Montero 
(2013)[81] 
2008-
2011 
Retrospective, 
cohort 
57 
Compare 
monotherapy and 
combination therapy 
VAP/ 
bacteraemia 
Colistin/vancomycin 
combination therapy** 
IV colistin 3 MU q8h, adjusted by 
BW and renal function + IV 
vancomycin 2 g/day with 1-h 
infusion, adjusted by the renal 
function 
Clinical cure 55.2%, 
28-day mortality 
48.3% 0.320, 
0.890 
Microbiological 
eradication 54.2% 
0.440 
Colistin monotherapy** IV colistin 3 MU q8h, adjusted by 
BW and renal function 
Clinical cure 67.9%. 
28-day mortality 
50% 
Microbiological 
eradication 65.2% 
Rigatto 
(2015)[82] 
2013-
2014 
Retrospective, 
cohort 
101 
Compare 
monotherapy and 
combination therapy 
Mainly 
pneumonia 
Polymyxin B-based 
combination therapy IV polymyxin B 1.5 to 3.0 
mg/kg/day in two divided doses 
± other antibiotics 
30-day mortality 
42.4% 
0.030 - - 
Polymyxin B 
monotherapy 
30-day mortality 
67.7% 
 Batirel 
(2014)[83] 
 2009- 
 2012 
 Retrospective,  
 cohort 
 250 
Compare 
monotherapy and 
combination therapy 
  
 
 Bacteraemia 
Colistin combination 
therapy** 
IV colistin 5mg/kg/day CBA in 2-3 
divided doses, with renal 
adjustment + carbapenems or 
sulbactam or other antibiotics 
Complete response 
46.3%, 14-day 
survival 68.2%  0.190,  
 0.140 
Microbiological 
eradication 79.9% 
 0.001 
Colistin monotherapy** 
IV colistin 5mg/kg/day CBA in 2-3 
divided doses, with renal 
adjustment 
Complete response 
30.6%, 14-day 
survival 55.5% 
Microbiological 
eradication 55.6% 
Compare different 
antibiotic 
combinations 
Colistin/carbapenem 
combination therapy** 
IV colistin 5mg/kg/day CBA in 2-3 
divided doses, with renal 
adjustment + imipenem 500 mg 
q6h or meropenem 
1 g q8h or doripenem 500 mg 
q8h 
Complete response 
49%, 14-day 
survival 70.6% 
 0.970,  
 0.790 
Microbiological 
eradication 81% 
 0.920 
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Colistin/sulbactam 
combination therapy** 
IV colistin 5mg/kg/day CBA in 2-3 
divided doses, with renal 
adjustment + ampicillin–
sulbactam 3 g q6h or sulbactam  
1.5 g q6h 
Complete response 
46.4%, 14-day 
survival 68.1% 
Microbiological 
eradication 79% 
Colistin /other 
antibiotic combination 
therapy** 
IV colistin 5mg/kg/day CBA in 2-3 
divided doses, with renal 
adjustment + other antibiotics 
Complete response 
39.5%, 14-day 
survival 62.8% 
Microbiological 
eradication 82% 
 
Lin 
(2015)[84] 
2004-
2007 
Retrospective, 
cohort 
173 
Compare 
monotherapy and 
combination therapy 
Pneumonia 
Sulbactam 
monotherapy IV sulbactam 1 g or 
ampicillin/sulbactam 3 g (at a 
rate of 2:1) q6-8h ± other 
antibiotics 
Clinical resolution 
63.6%, 30-day 
mortality 36.4% 0.906, 
0.947 
Airway eradication 
without relapse 
89.5% 
0.694 
Sulbactam-based 
combination therapy 
Clinical resolution 
65.1%, 30-day 
mortality 37.2% 
Airway eradication 
without relapse 
81.3% 
Shin 
(2012)[85] 
2009-
2010 
Retrospective, 
cohort 
27 
Compare 
monotherapy and 
combination therapy 
Various, 
mainly VAP 
Tigecycline 
monotherapy IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg ± other 
antibiotics 
Clinical success 
58.5%, 14-day 
mortality 5.9% 0.561, 
0.260 
Microbiological 
success 76.5% 
0.097 
Tigecycline combination 
therapy 
Clinical success 
70%, 14-day 
mortality 0% 
Microbiological 
success 100% 
Tasbakan 
(2011)[86] 
2009-
2011 
Retrospective, 
cohort 
72 
Compare 
monotherapy and 
combination therapy 
Pneumonia 
Tigecycline 
monotherapy 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg  
30-day mortality 
52.1% 
>0.050 
Microbiological 
eradication 60.9% 
>0.050 
Tigecycline-based 
combination therapy 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg + 
imipenem/cilastatin 500mg q6h 
or amikacin 1 g q24h or 
netilmicin 300 mg q24h or 
cefoperazone/sulbactam 2 g q8h 
30-day mortality 
57.1% 
Microbiological 
eradication 67.3% 
Kim 
(2016)[87] 
2009-
2010 
Retrospective, 
cohort 
70 
Compare different       
antibiotic 
combinations 
Pneumonia 
Tigecycline-based 
therapy 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg ± other 
antibiotics 
Clinical success 
47%, 30-day 
mortality 33% 0.950, 
0.770 
Microbiological 
success 23% 
0.540 
Colistin-based therapy 
IV colistin 4.5 MU q12h after a 
loading dose of 9 MU, with renal 
adjustment ± other IV antibiotics 
Clinical success 
48%, 30-day 
mortality 33% 
Microbiological 
success 30% 
 Compare    
 monotherapy and  
 combination  
Monotherapy Either tigecycline or colistin 
Clinical success 
39%, 30-day 
mortality 33% 
0.110, 
0.560 
Microbiological 
success 22% 
0.250 
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 therapy 
Combination therapy 
Either tigecycline or colistin-
based therapy 
Clinical success 
59%, 30-day 
mortality 33% 
Microbiological 
success 35% 
Lee 
(2013) 
[88] 
2007-
2011 
Retrospective, 
cohort 
386 
Compare different 
antibiotic 
combinations 
HAI 
Tigecycline-based 
therapy
#
 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg ±  
other antibiotics 
Favourable 
outcome 69.2%, 
mortality 36.1% <0.001, 
0.930 
Microbiological 
eradication 1.1% 
<0.001 
Non-tigecycline based 
therapy
#
 
IV imipenem/cilastatin 500 mg 
and sulbactam 1 g q6h 
Favourable 
outcome 50%, 
mortality 38.3% 
Microbiological 
eradication 11.7% 
Lim 
(2011) 
[89]  
2000-
2007 
Retrospective, 
cohort 
70 
Compare different 
antibiotic 
combinations 
Bacteraemia 
Colistin-based 
therapy** 
IV colistimethate sodium 2.5-
5.0 mg/kg per day in 2-3 
divided doses, renal adjusted 
30-day mortality 
35.5% 
0.800 - - 
Non-colistin based 
therapy** 
Other antibiotics 
30-day mortality 
38.5% 
Ye (2016) 
[90] 
2004-
2010 
Retrospective, 
cohort 
168 
Compare different 
antibiotic 
combinations 
Pneumonia 
Tigecycline-based 
therapy** 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg ±  
other antibiotics 
30-day mortality 
33.3% 
0.618 
Eradication 33.3% 
<0.001 
Sulbactam-based 
therapy** 
IV sulbactam 1 g or 
ampicillin/sulbactam 3 g (at a 
rate of 2:1) q6-8h ±  other 
antibiotics 
30-day mortality 
29.8% 
Eradication 63.5% 
Chuang 
(2014) 
[91]
 
 
2009-
2010 
Retrospective, 
matched 
cohort 
168 
Compare different 
antibiotic 
combinations 
Pneumonia 
Tigecycline-based 
therapy 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg ± 
other antibiotics 
Mortality 60.7%  
0.040 - - 
Colistin-based 
therapy** 
IV colistin 2.5–5 mg/kg/day CBA  
in 2–3 divided doses ± other 
antibiotics  
Mortality 44% 
Cheng 
(2015) 
[92] 
2010-
2013 
Prospective, 
cohort 
55 
Compare different 
antibiotic 
combinations 
Mainly 
pneumonia/ 
bacteraemia 
Colistin/carbapenem 
combination therapy** 
IV colistin 5mg/kg/day CBA in 2-
3 divided doses, with renal 
adjustment + carbapenems 
14-day mortality 
15%, breakthrough 
bacteraemia 0% 
0.105, 
0.059 
- - 
Colistin/tigecycline 
combination therapy** 
IV colistin 5mg/kg/day CBA in 2-
3 divided doses, with renal 
adjustment + IV tigecycline 50 
mg q12h, after a loading dose 
of 100 mg  
14-day mortality 
35%, breakthrough 
bacteraemia 18% 
14-day mortality was associated with the use of colistin-tigecycline in the subgroup with tigecycline MIC > 2 mg/L 
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compared with the use of colistin-carbapenem (hazard ratio, 6.93; 95% CI, 1.61–29.78; p = 0.009). 
Jean 
(2016) 
[93] 
2013 
Prospective, 
cohort 
84 
Compare different 
antibiotic 
combinations 
VAP 
Tigecycline/imipenem 
combination therapy Standard dose (not specified) 
30-day survival rate 
85.7% 
0.007 - - 
Sulbactam/imipenem 
combination therapy 
Standard dose (not specified) 
30-day survival rate 
35.7% 
In the tigecycline group, patients were switched from sulbactam-based therapy to tigecycline-based therapy after 
failure to respond to 3-day sulbactam–imipenem/cilastatin therapy 
He (2016) 
[94] 
2011-
2013 
Retrospective, 
cohort 
44 
Compare different 
antibiotic 
combinations 
VAP 
Tigecycline-based 
combination therapy 
IV tigecycline 50 mg q12h, after 
a loading dose of 100 mg + IV 
imipenem/meropenem 1 g q8h 
+ IV cefoperazone/sulbactam 3 
g q8h 
Clinical cure 50%, 
all-cause mortality 
50% 
1.000 
Microbiological 
eradication 15% 
0.264 
Non-tigecycline based 
combination therapy 
IV imipenem/meropenem 1 g 
q8h + IV 
cefoperazone/sulbactam 3 g 
q8h 
Clinical cure 45.8%, 
all-cause mortality 
54.2% 
Microbiological 
eradication 29.2% 
Chen 
(2014)[95] 
2007-
2011 
Retrospective, 
cohort 
135 
Compare different 
route of 
administration 
Pneumonia 
Inhaled colistin** Neb colistin 2 MU q12h  
28-day mortality 
11.3% 
0.167 
14-day eradication 
61.1% 
0.001 
Other antibiotic 
therapies** 
Not specified 
28-day mortality 
16.7% 
14-day eradication 
29.6% 
Kuo 
(2012)[96] 
2009-
2010 
Retrospective, 
case-control 
78 
Compare different 
route of 
administration 
Pneumonia Inhaled colistin**  Neb colistin 2 MU q12h 
28-day mortality 
12.8% 
0.723 
Eradication within 
14 days 84.6% 
<0.001 
 
Other antibiotic 
therapies** 
Other antibiotics 
28-day mortality 
10.3% 
Eradication within 
14 days 10.3% 
Jang 
(2017)[97] 
2013-
2016 
Retrospective, 
cohort 
95 
Compare different 
route of 
administration 
VAP 
IV colistin based 
therapy 
IV colistin 4.5 MU q12h after a 
loading dose of 9 MU, with 
renal adjustment ± other IV 
antibiotics 
Clinical 
cure/improvement 
79.6%, mortality 
13.6% 0.719, 
0.438 
Microbiological 
eradication 65% 
0.921 
Inhaled colistin based 
therapy 
Neb Colistin 4.5 MU q8h ± 
other IV antibiotics 
Clinical 
cure/improvement 
76.5%, mortality 
19.6% 
Microbiological 
eradication 66% 
Kofteridis 
(2010)[98] 
2005-
2008 
Retrospective, 
case-control 
86 
Compare different 
route of 
administration 
VAP IV colistin only** 
IV colistin 9 MU divided in 3 
divided doses, with renal 
adjustment  
Clinical cure 32.5%, 
mortality 26% 
0.050, 
0.289 
Bacteriological 
eradication 50% 
0.679 
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Inhaled colistin + IV 
colistin** 
Neb colistin 2 MU q12h 
Clinical cure 54%, 
mortality 16% 
Bacteriological 
eradication 45% 
Kalin 
(2012)[99] 
2011 
Retrospective, 
cohort 
45 
Comparing different 
doses 
VAP 
High dose IV colistin
# IV colistimethate sodium 2.5 
mg/kg q6h 
14-day clinical cure 
7%, mortality 67% 
0.250, 
0.180 
14-day 
bacteriological 
clearance 64% 
0.19 Normal dose IV colistin
# IV colistimethate sodium 2.5 
mg/kg q12h 
14-day clinical cure 
30%, mortality 45% 
14-day 
bacteriological 
clearance 65% 
Low dose IV colistin# 
Adjusted according to the 
creatinine clearance 
14-day clinical cure 
30%, mortality 40% 
14-day 
bacteriological 
clearance 75% 
Compare different 
route of 
administration 
IV colistin only
# 
As above 
14-day clinical cure 
38%, mortality 44% 
0.130, 
0.650 
14-day 
bacteriological 
clearance 69% 
0.73 
IV colistin + inhaled 
colistin
# Neb colistin 2 MU q12h 
14-day clinical cure 
14%, mortality 55% 
14-day 
bacteriological 
clearance 76% 
Pan (2018) 
[100]  
2013-
2017 
Retrospective, 
cohort 
61 
Compare different 
route of 
administration 
Meningitis/ 
ventriculitis 
Intrathecal/intraventric
ular polymyxin B-based 
therapy 
IT/IVT polymyxin B 50,000 
units/day q12h + IV polymyxin B 
450,000 units q12h ± other IV 
antibiotics 
28-day mortality 
8.70%; clinical 
efficacy 95.6% 0.010; 
<0.001 
Microbiological 
clearance 91.3% 
<0.001 
Other IV antibiotic 
therapies 
Other IV antibiotics 
28-day mortality 
55.26%, clinical 
efficacy 23.7% 
Microbiological 
clearance 18.4% 
VAP, ventilator-associated pneumonia; IV, intravenous; Neb, nebulized; MU, million units; CBA, colistin-based activity; IT, intrathecal; IVT, intraventricular; BW, body weight; q8h, every 8 hours; 
q12h, every 12 hours. 
** Colistin MIC (minimum inhibitory concentration) testing by methods other than broth microdilution. 
# 
Colistin MIC testing not done/mentioned. 
*Broth microdilution is the preferred method of susceptibility testing for colistin, as per European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendation [63]. 
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Table 2: Characteristics and outcomes of RCTs on the treatment of MDR Acinetobacter spp. infections 
Reference 
Study 
period 
Study design 
Number 
of 
patients 
Site of 
infection 
Treatment given Dose of antimicrobials 
Mortality 
prediction 
score  
Clinical outcome 
p-
value  
Microbiological 
outcome  
p-value 
Rattanaumpawan 
(2010)[103] 
2006-
2009 
Prospective, 
RCT, open-
labelled 
100 VAP 
Inhaled colistin 
group
# 
Neb colistin 2 MU q12h + IV 
antibiotics 
19.1(5.8)
† 
Favourable 
clinical outcome 
51.0%, 28-day 
mortality 39.2%  0.840, 
0.800 
Favourable 
microbiological 
outcome 60.9%  
0.030 
Placebo group 
Neb normal saline + IV 
antibiotics 
18.5 (4.7)
 †
 
Favourable 
clinical outcome 
53.1%, 28-day 
mortality 36.7%  
Favourable 
microbiological 
outcome 38.2% 
Paul (2018)[104] 
2013-
2016 
Prospective, 
RCT, open-
labelled 
406 
Mainly 
pneumonia/ 
bacteraemia 
Colistin 
monotherapy
# 
IV colistin 4.5 MU q12h after 
a loading dose of 9 MU, 
with renal adjustment  
   5 (3–8)
‡
 
Clinical failure 
79%, 28-day 
mortality 43% 0.172, 
0.781 
Microbiological 
failure 31% 
0.489 
Colistin/meropenem 
combination 
therapy
# 
IV colistin + IV meropenem 
2 g q8h with 3-h infusion, 
both with renal adjustment 
   6 (4–9)
‡
 
Clinical failure 
73%, 28-day 
mortality 45% 
Microbiological 
failure 35% 
Durante-
Mangoni 
(2013)[105] 
2008-
2011 
Prospective, 
RCT, open-
labelled 
210 Mainly VAP 
Colistin 
monotherapy
# 
IV colistin 2 MU q8h, with 
renal adjustment  
 39.0 (11.1)
¶
 
30-day mortality 
42.9% 
0.950 
Bacteriological 
eradication 44.8% 
0.034 Colistin/rifampin 
combination 
therapy
# 
IV colistin + IV rifampin 600 
mg q12h 
 40.8 (10.8)
¶
 
30-day mortality 
43.3% 
Bacteriological 
eradication 60.6% 
Aydemir 
(2013)[106] 
2011-
2012 
Prospective, 
RCT, open-
labelled 
43 VAP 
Colistin 
monotherapy 
IV colistin 9 MU divided into 
3 divided doses, with renal 
adjustment 
 18.0 (4.9)
†
 
Clinical response 
49%, mortality 
63.6% 0.654, 
0.171 
Microbiological 
response 59.1% 
0.597 
Colistin/rifampin 
combination 
therapy 
IV colistin + PO rifampin 600 
mg/day 
 20.1 (6.8)
†
 
Clinical response 
52%, mortality 
38.1% 
Microbiological 
response 71.4% 
Sirijatuphat 
(2014)[107] 
2010-
2011 
Prospective, 
RCT, open-
labelled 
94 Mainly VAP 
Colistin 
monotherapy
#
 
IV colistin 5 mg of CBA/kg 
BW/day  
 21.9 (7.9)
†
 
Favourable 
clinical response 
55.3%, 28-day 
mortality 23.1% 
0.835, 
0.578 
Microbiological 
response 81.2% 
0.010 
Colistin/fosfomycin 
combination 
IV colistin + IV fosfomycin 4 
g q12h 
 23.0 (6.4)
†
 
Favourable 
clinical response 
Microbiological 
response 100% 
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therapy
# 
59.6%, 28-day 
mortality 16.3% 
Makris 
(2018)[108] 
Not 
specified 
Prospective, 
RCT, open-
labelled 
39 VAP 
Colistin 
monotherapy
# 
IV colistin 3 MU q8h, with 
renal adjustment  
  14.5 (3.1)
†
 
Clinical response 
15.8%, mortality 
63% 
0.001, 
NS 
Microbiological 
eradication 1/3 
0.191 Colistin/ampicillin- 
sulbactam 
combination 
therapy
# 
IV colistin + IV ampicillin-
sulbactam 6 g q6h, both 
with renal adjustment 
 16.5 (4.7)
†
 
Clinical response 
70%, mortality 
50% 
Microbiological 
eradication 10/14 
Abdellatif 
(2016)[109] 
2013-
2015 
Prospective, 
RCT, single-
blind 
149 VAP 
Inhaled colistin/IV 
imipenem
# 
Neb colistin 4 MU q8h + IV 
imipenem 1 g q8h 
   39 (13)
¶
 
Favourable 
clinical outcome 
67.1%, 28-day 
mortality 27.4% 0.590, 
0.700 
Time to bacterial 
eradication 9.89 ± 
2.7 days 
0.023 
IV colistin/IV 
imipenem
# 
IV Colistin 4.5 MU q12h 
after a loading dose of 9 
MU, with renal adjustment 
+ IV imipenem 1 g q8h 
   40 (14)
¶
 
Favourable 
clinical outcome 
72.3%, 28-day 
mortality 23.7% 
Time to bacterial 
eradication 11.26 ± 
3 days 
Betrosian 
(2008)[110] 
Not 
specified 
Prospective, 
RCT, open-
labelled 
28 VAP 
Colistin 
monotherapy** 
IV colistin 3 MU q8h    14 (2)
†
 
Clinical success 
60%, 14-day 
mortality 20% 
NS, NS 
Bacteriological 
eradication 46.6% 
NS 
Ampicillin-
sulbactam 
monotherapy** 
IV ampicillin-sulbactam (2:1) 
9 g q8h 
   14 (5)
†
 
Clinical success 
61.5% 14-day 
mortality 15.3% 
Bacteriological 
eradication 46.1% 
RCT, randomized controlled trial; CRAB, carbapenem-resistant Acinetobacter baumannii; VAP, ventilator-associated pneumonia; UTI, urinary tract infection; IV, intravenous; Neb, nebulized; MU, 
million units; CBA, colistin-based activity; BW, body weight; q6h, every 6 hours; q8h, every 8 hours; q12h, every 12 hours; NS, not significant; SD, standard deviation; IQR, inter quartile range; † 
APACHE (Acute Physiology And Chronic Health Evaluation) II score; ‡ SOFA (Sequential Organ Failure Assessment) score; ¶ SAPS (Simplified Acute Physiology) II score. For the mortality 
prediction scores, data are presented as mean (SD) or median (IQR). 
** Colistin MIC (minimum inhibitory concentration) testing by methods other than broth microdilution. 
# 
Colistin MIC testing not done/mentioned. 
*Broth microdilution is the preferred method of susceptibility testing for colistin, as per European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendation [63]. 
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Table 3: Studies evaluating dose optimization of antibiotics used for MDR Acinetobacter spp. infections  
Reference 
Study 
design 
Method(s) 
Duration 
of study  
Antibiotics tested Outcome  
Hagihara 
(2014)[115] 
In vitro PD model 24h 
1 mg/kg polymyxin B q12h  
Combination therapy with polymyxin B plus 100 mg or 200 mg tigecycline q12h 
achieved a greater reduction in bacterial density than did therapy with polymyxin B 
alone. 
100 mg tigecycline q12h  
200 mg tigecycline q12h  
Polymyxin B + tigecycline 100 mg 
Polymyxin B + tigecycline 200 mg 
Li (2014)[116] In vitro HFIM 168h 
0.5 g given q8h with a 0.5-h infusion Not bactericidal 
0.5 g meropenem q8h with a 3-h infusion Not bactericidal 
1.0 g given q8h with a 0.5-h infusion 3-log10 CFU/ml bacterial killing; did not suppress the emergence of resistance  
1.0 g meropenem q8h with a 3-h infusion 3-log10 CFU/ml bacterial killing; did not suppress the emergence of resistance  
2.0 g given q8h with a 0.5-h infusion 3-log10 CFU/ml bacterial killing; suppressed emergence of resistance; %T>MPC ≥ 20 
2.0 g meropenem q8h with a 3-h infusion 3-log10 CFU/ml bacterial killing; suppressed emergence of resistance; %T>MPC ≥ 20 
Menegucci 
(2016)[31] 
In silico MCS - 
4.0 g fosfomycin q8h with 1-h infusion 
PTA ≥ 0.9 for %fT>MIC ≥ 70% (MIC 16 mg/L) 6.0 g fosfomycin q6h with a 1-h infusion 
8.0 g fosfomycin q8h with a 1-h infusion 
4.0 g fosfomycin q8h with 3-h infusion PTA ≥ 0.9 for %fT>MIC ≥ 70% (MIC 32 mg/L) 
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6.0 g fosfomycin q6h with a 3-h infusion 
8.0 g fosfomycin q8h with a 3-h infusion 
1.5 g meropenem q6h with 0.5-h infusion 
PTA ≥ 0.9 for %fT>MIC ≥ 40% (MIC 4 mg/L) 
1.0 g meropenem q8h with a 3-h infusion 
1.5 g meropenem q6h with a 3-h infusion 
2.0 g meropenem q8h with a 3-h infusion 
Cai (2017)[117] In vitro PD model 24h 
5 mg/kg/day colistin in 3 divided doses 
Combination of colistin with either regimen of tigecycline achieved a greater reduction 
in bacterial density and AUBC than colistin alone. A combination of tigecycline (high 
dose) and colistin may be an effective therapy to prevent the emergence of resistance 
during treatment of MDR-AB synergistically. 
100 mg loading followed by 50 mg tigecycline 
q12h  
200 mg loading followed by 100 mg tigecycline 
q12h 
Colistin + 100 mg loading followed by 50 mg 
tigecycline q12h  
Colistin + 200 mg loading followed by 100 mg 
tigecycline q12h 
Matsumoto 
(2017)[118] 
In vivo 
Murine 
pneumonia 
model 
96h 
2.0 g cefiderocol q8h with a 3-h infusion 
2 g every 8 h as a 3-h infusion for 4 days produced a >3 log10 reduction in the number 
of viable cells of these carbapenem-resistant isolates in the lungs.  
2.0 g cefiderocol q8h with a 1-h infusion 
Lee (2013)[119] In vitro PD model 72h 
Colistin at 0.5 mg/L + rifampin with a Cmax of 5 
mg/L Combinations resulted in substantially greater killing at the low inoculum; 
combinations containing 2 and 5 mg/L colistin increased killing at the high inoculum. 
Combinations were additive or synergistic with all colistin concentrations Emergence 
of colistin-resistant subpopulations was completely suppressed in the colistin-
susceptible isolate with all combinations at both inocula. 
Colistin at 2 mg/L + rifampin with a Cmax of 5 
mg/L 
Colistin at 5 mg/L + rifampin with a Cmax of 5 
mg/L 
Housman 
(2013)[120] 
In vitro PD model 24h 
9.0 g ampicillin/sulbactam q8h with 3-h infusion 
+ 2.0 g doripenem q8h with 4-h infusion AUBC 87.8+21.0 
9.0 g ampicillin/sulbactam q8h with 3-h infusion AUBC 100.6+33.0 
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+200 mg tigecycline q12h with 30-min infusion 
9.0 g ampicillin/sulbactam q8h with a 3-h 
infusion 
AUBC 116.7+31.6 
3.0 g ampicillin/sulbactam q6h with 30-min 
infusion + 200 mg tigecycline q12h with 30-min 
infusion 
AUBC 134+31.5 
2.0 g doripenem q8h with 4-h infusion + 200 mg 
tigecycline q12h with a 30-min infusion 
AUBC 142.7+16.9 
Rao (2016)[121] In vitro  HFIM 48h 
Polymyxin B traditional monotherapy: free 
steady-state concentration (fCss) of 2 mg/L 
administered as a continuous infusion 
Bacteriostatic 
Polymyxin B traditional monotherapy: as above 
but with an fCss of 5 mg/L administered as a 
continuous infusion 
Initial killing up to 3 log10 in the first 6 h, followed by substantial regrowth 
Doripenem monotherapy: fCmax of 25 mg/L q8h Bacteriostatic 
Polymyxin B traditional (fCss of 2 mg/L 
continuous infusion) and doripenem (fCmax of 25 
mg/L q8h) 
Synergistic with a 7.5 log10 CFU/mL reduction by 48 h. This combination regimen 
resulted in complete eradication at 72 h that was sustained until 192 h then regrowth 
at 240 h. Complete suppression of resistant subpopulations. 
Polymyxin B ‘front-loaded’ (fCss of 5 mg/L 
continuous infusion for 24 h followed by fCss of 2 
mg/L thereafter) and doripenem (fCmax of 25 
mg/L q8h) 
Rapid and extensive initial killing (>8 log10 CFU/mL) with an improved time to 
eradication. Complete eradication of A. baumannii at 48 h. Complete suppression of 
resistant subpopulations. 
Polymyxin B ‘burst 2’ (fCss of 2 mg/L continuous 
infusion for 24 h followed by no polymyxin B 
thereafter) and doripenem (fCmax of 25 mg/L 
q8h) 
>8 log10 CFU/mL reduction by 72 h with ∼6 log10 regrowth beyond 144 h 
Polymyxin B ‘burst 5’ (fCss of 5 mg/L continuous 
infusion for 24 h followed by no polymyxin B 
thereafter) and doripenem (fCmax of 25 mg/L 
q8h) 
Rapid initial and sustained killing similar to the combination of polymyxin B ‘front-
loaded’ and doripenem regimen. Complete suppression of resistant subpopulations. 
Doripenem ‘burst’ (fCmax of 25 mg/L every 8 h × 3 
doses followed by no doripenem thereafter) and 
polymyxin B traditional regimen (fCss of 2 mg/L 
continuous infusion). 
Regrowth after the initial ∼3 log10 reductions in CFU/mL between 24 and 48 h.  
Lenhard In vitro  HFIM 336h 8/4 g ampicillin-sulbactam q8h Bacterial eradication by 144 h, albeit with killing over the first 72 h that was slower 
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(2017)[122] than that with the ampicillin-sulbactam double combinations. 
2 h meropenem q8h, with a 3-h infusion Failed to achieve a ≥1-log10 reduction 
3.33 mg/kg polymyxin B, then 1.43 mg/kg q12h  Failed to achieve a ≥1-log10 reduction 
8/4 g ampicillin-sulbactam q8h + 2 h meropenem 
q8h, with a 3-h infusion 
Sustained bactericidal activity 
3.33 mg/kg polymyxin B, then 1.43 mg/kg q12h + 
2 h meropenem q8h with 3-h infusion 
Reduced counts by ≥2 log10 at 6 h, stasis ensued for 24 h, but by 48 h, counts had risen 
above 10
8
CFU/ml. 
8/4 g ampicillin-sulbactam q8h + 3.33 mg/kg 
polymyxin B, then 1.43 mg/kg q12h  
Sustained bactericidal activity 
Liu (2016)[62] In vitro PD model 24h 
1 g meropenem with 3-h infusion + 1 mg/L 
colistin  
> 3 log10 bacterial killing, better bacterial killing compared to monotherapy 
2 g meropenem with a 3-h infusion + 1 mg/L 
colistin  
Roberts 
(2009)[123] 
In silico MCS - 
2 g meropenem q8h as bolus %fT>MIC 40% = 41% (MIC 16 mg/L) 
2 g meropenem q8h, with a 4-h infusion %fT>MIC 40% = 69% (MIC 16 mg/L) 
2 g meropenem q8h, with a 4-h infusion %fT>MIC 40% = 100% (MIC 16 mg/L) 
Nicholson 
(2009)[124] 
In vivo 
Prospective, 
cohort 
- 1 g doripenem q8h, with 4-hr infusion Overall microbiologic cure: 78.6%, 66.6% for MIC ≥16 mg/L 
Jaruratanasirikul 
(2013)[125] 
In vivo 
Prospective, 
cohort 
 1 g meropenem q8h, as bolus %fT>MIC 40% = 87.7% (MIC 4 mg/L) 
- 1 g meropenem q8h ,with a 3-hour infusion %fT>MIC 40% =98.8% (MIC 4 mg/L) 
 2 g meropenem q8h, with a 3-hour infusion %fT>MIC 40% = 99.9% (MIC 4 mg/L) 
Jaruratanasirikul 
(2016)[126] 
In silico MCS 
 1g sulbactam q6h, with a 4-hour infusion %fT>MIC 60% = 75.7% (MIC 16 mg/L) 
 2g sulbactam q8h, with a 1-hour infusion %fT>MIC 60% = 52.9% (MIC 16 mg/L) 
 2g sulbactam q8h, with a 4-hour infusion %fT>MIC 60% = 81.6% (MIC 16 mg/L) 
- 2g sulbactam q6h, with a 1-hour infusion %fT>MIC 60% = 81.3% (MIC 16 mg/L) 
 2g sulbactam q6h, with a 4-hour infusion %fT>MIC 60% = 93.5% (MIC 16 mg/L) 
 3g sulbactam q8h, with a 1-hour infusion %fT>MIC 60% = 78.9% (MIC 16 mg/L) 
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 3g sulbactam q8h, with a 4-hour infusion %fT>MIC 60% = 89.2% (MIC 16 mg/L) 
 3g sulbactam q6h, with a 1-hour infusion %fT>MIC 60% = 86.9% (MIC 16 mg/L) 
 3g sulbactam q6h, with a 4-hour infusion %fT>MIC 60% = 98.0% (MIC 16 mg/L) 
 4g sulbactam q8h, with a 1-hour infusion %fT>MIC 60% = 82.8% (MIC 16 mg/L) 
 4g sulbactam q8h, with a 4-hour infusion %fT>MIC 60% = 92.6% (MIC 16 mg/L) 
Xie (2014)[127] In silico MCS 
 
100 mg tigecycline q12h 
CFR 54.67% (skin and soft tissue infection) 
- CFR 48% to 88% (intra-abdominal infection) 
q8h, every 8 hours; q12h, every 12 hours, CFU, colony forming unit; PTA, probability of target attainment; HFIM, hollow-fibre infection model; PD, pharmacodynamic; MCS, Monte-Carlo 
simulation; %T>MPC, percentage of time that the drug concentrations exceeded the mutant prevent concentration;  %fT>MIC, percentage of time that the free drug concentration remains above 
the MIC of an offending pathogen during a dosing interval; AUBC, area under the bactericidal curve; fCss, fraction of the steady-state concentration; fCmax, maximal unbound drug concentration; 
MIC, minimum inhibitory concentration; CFR, cumulative fraction response (probability of target attainment for a specific drug dose, according to a MIC distribution of a specific 
microorganism).[128] 
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Table 4: The PK/PD index and the optimal magnitude of antibiotics against MDR A. 
baumannii. 
 
Antibiotic  Study model  PK/PD index 
PK/PD index 
magnitude for 
optimal antimicrobial 
activity 
References  
Sulbactam 
Neutropenic murine thigh infection 
model 
% fT>MIC   
>60
@ 
[129] 
Neutropenic murine lung infection 
model 
>40
@ 
Colistin 
Neutropenic murine lung infection 
model 
fAUC/MIC 
8.18-42.1
# 
 
[131] 
Neutropenic murine thigh infection 
model 
6.98-13.6
# 
Neutropenic murine thigh infection 
model 
7.4-17.6
* [101] 
Carbapenem  
Neutropenic murine thigh infection 
model 
% fT>MIC   47.5
* [135] 
Fosfomycin In vivo, prospective cohort study % fT>MIC   60-70 
[136] 
Tigecycline 
In silico population PK model (for 
complicated skin and skin-structure 
infection) 
fAUC/MIC 
17.9 
[137] 
 
In silico population PK model (for 
complicated skin and skin-structure 
infection) 
6.96 
[138] 
Abbreviations: fAUC/MIC, the ratio of the area under the concentration-time curve during a 24-hour period to MIC; % fT>MIC, 
percentage of time that the free drug concentration remains above the MIC of an offending pathogen during a dosing 
interval; PK/PD, pharmacokinetic/pharmacodynamics; 
#
1-log kill; *2 -log kill 
@
3-log kill. 
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Table 5: Microbiological susceptibility, recommended doses and administration of antibiotics 
for the treatment of MDR A. baumannii. 
 
Antibiotic Dose Administration 
(intravenous) 
MIC90 of agent 
against A. 
baumannii 
(μg/ml) 
Creatinine 
clearance 
(mL/min) 
References 
Sulbactam 2 g every 6h 4-hour infusion 4
 
90 
[130] 
Tigecycline 200mg loading dose then 
100 mg every 12h 
- 0.25 - 
[137, 138] 
Minocycline  100 mg every 12h - - - 
[140-142]
 
Rifampin 600 mg every 12h - ≤4 - 512 
 
 
- 
[106]
 
Meropenem  2 g every 8h 3-hour infusion 8 Normal renal 
function 
[31, 123] 
Fosfomycin  8 g every 8h 3-hour infusion 32 Normal renal 
function 
[31] 
Cefiderocol 2 g every 8h 3-hour infusion ≤4 
 
Normal renal 
function 
[118, 143] 
Colistin Loading dose: 9 million IU loading dose                                 1-2 
 
Daily dose*: in 2 divided doses 12 h apart according to creatinine clearance. 
*Daily dose of CBA (mg) = Css,avg target (mg/L) × 10
(0.0048 × CrCl + 1.825)
, to target a 
plasma colistin Css,avg of 2 mg/L, depending on the patient’s creatinine clearance.  
 
[132] 
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Table 6: Microbiological susceptibility of MDR A. baumannii to new antibiotics. 
 
Antibiotic  Antimicrobial class MIC90  against MDR 
Acinetobacter spp 
(mg/L) 
References  
Ceftazidime/avibactam 
Cephalosporin/beta-lactamase 
inhibitor combination 
>32 
[150, 151] 
Cefepime/zidebactam >32 
[152, 153] 
Imipenem/relebactam Carbapenem/beta-lactamase 
inhibitor combination 
>32 
[154, 155] 
Meropenem/vaborbactam >32 
[156] 
Aztreonam/avibactam 
Monobactam/beta-lactamase 
inhibitor combination 
≥64 
[157-160] 
Cefiderocol Siderophore cephalosporin ≤8 
[161-166] 
Plazomicin Aminoglycoside 16 
[49, 167] 
Apramycin Aminoglycoside 32 
[168] 
Eravacycline  Fluorocycline  1 
[169-171] 
Imipenem/LN-1-255 Carbapenem/penicillin sulphone 
inhibitor combination 
≤8 
[172] 
Meropenem/LN-1-255 ≤8 
[172] 
Imipenem/ WCK 4234 Carbapenem/ beta-lactamase 
inhibitor 
≤2 [173] 
Meropenem/ WCK 4234 ≤2 
Sulbactam/ ETX2514 
Beta-lactam/beta-lactamase inhibitor 
combination 
4 
[174] 
Delafloxacin Fluoroquinolone ≤16 
[175, 176] 
WFQ-228 Fluoroquinolone 1 
[177] 
TP-6076 Fluoroquinolone 0.008 -0.5 
[178] 
SPR741/rifampin polymyxin-B-derived molecule 0.5 
[179, 180] 
MDR, multi-drug resistant; MIC90, the minimum inhibitory concentration required to inhibit the growth of 90% of the 
bacteria.  
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Table 7: The PK/PD index and the optimal magnitude for novel agents with in vitro activity 
against MDR A. baumannii. 
 
Antibiotic  Study model  PK/PD index PK/PD index 
magnitude for 
optimal antimicrobial 
activity 
References  
Cefiderocol Pseudomonas aeruginosa 
neutropenic murine thigh infection 
model 
% fT>MIC   >62
*
 
[148] 
Plazomicin Carbapenem-resistant Klebsiella 
pneumonia neutropenic murine lung 
infection model 
fAUC/MIC 39
a* 
32
b* 
[181] 
Carbapenem-resistant Klebsiella 
pneumonia neutropenic murine 
thigh infection model 
95
# [144] 
Eravacycline  Escherichia coli neutropenic murine 
thigh infection model 
fAUC/MIC 32.60 ± 10.85
# 
 
[149] 
Immunocompetent murine thigh 
infection model 
fAUC/MIC 5.6 ± 5.0
# 
 
[182] 
Imipenem/LN-1-255  
N/A Meropenem/LN-1-
255 
Sulbactam/ETX2514 Acinetobacter baumannii 
neutropenic murine thigh infection 
model  
% fT>MIC  
(sulbactam) 
% T>CT (ETX2514) 
50
* 
 
50
* 
[145] 
Delafloxacin Klebsiella pneumoniae neutropenic 
murine lung infection model 
fAUC/MIC 80-200
# [146, 147] 
Abbreviations: fAUC/MIC, the ratio of the area under the concentration-time curve during a 24-hour period to MIC; % fT>MIC, 
percentage of time that the free drug concentration remains above the MIC of an offending pathogen during a dosing 
interval; %T>CT, time above the critical threshold; PK/PD, pharmacokinetic/pharmacodynamics; N/A, not available 
a
 Plasma fAUC/MIC target; 
b 
Epithelial lining fluid (ELF) fAUC/MIC target; 
#
1-log kill; *2 -log kill 
 
 
